ArticleScientific reports2025
Astragalus mongholicus and Hedyotis diffusa willd inhibit cell proliferation by attenuating the miR-582-3p-p27 signaling pathway in LUAD.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanistic studies ofFrontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Previous studies conducted by the same group of researchers found that Traditional Chinese Medicine Astragalus mongholicus Bunge and Hedyotis diffusa Willd (A-H) significantly suppressed the cell proliferation of lung adenocarcinoma (LUAD). MicroRNAs are considered promising candidates for cancer diagnosis and treatment. This study focused on miR-582-3p as the primary subject of investigation to explore the mechanism by which A-H inhibits cell proliferation through miR-582-3p. The overexpressing and silencing miR-582-3p cell models were established by using lentiviral transfection technology. CCK-8 assay (24 h, 48 h, 72 h) and clone formation assay (1 w) were employed to detect the proliferation of A549 cells. Moreover, flow cytometry analysis (24 h) was performed to detect the cell cycle. Western blotting (WB) and a luciferase reporter assay were also used to measure the expression of cell cycle-related proteins and verify the direct interaction between miR-582-3p and p27, respectively. The LV-miR-582-3p inhibitor + shRNA-p27 stable A549 cells were constructed in the same manner to repeat the above-mentioned procedure. The CCK-8 assay was conducted to assess the effects of various concentrations of A-H on the proliferation of A549 cells. A-H-containing serum was prepared to intervene in LV-miR-582-3p and mimic A549 cells. Subsequently, the same procedure was repeated, as described earlier. Results indicated a direct interaction between miR-582-3p and p27. Furthermore, miR-582-3p was found to enhance the proliferation of A549 cells by regulating cell cycle-related proteins, specifically p27. It was also observed that A-H-containing serum inhibited the proliferation of A549 cells through the miR-582-3p-p27 signaling pathway. The study findings revealed the underlying molecular mechanisms of miR-582-3p in the development and prognosis of A549 LUAD cells. In addition, A-H inhibited LUAD proliferation through the miR-582-3p-p27 signaling pathway. These findings may provide a new understanding of the use of Chinese medicine in treating lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.